The Phase I study is expected to yield important information about the safety and immunogenicity of VaxInnate’s hemagglutinin (HA)-flagellin flu vaccine candidate. The study is taking place at the University of Rochester in New York.
The open-label, escalating, dose-ranging study includes 56 healthy adult volunteers aged 18-49 years who are receiving a single intramuscular dose ranging from 0.1ug to 8ug of vaccine candidate. There will be six months of follow-up after administration of the vaccine candidate. Results are expected in early 2009.
Alan Shaw, CEO of VaxInnate, said: “The advance of VaxInnate’s second vaccine candidate into clinical development is an important milestone in our comprehensive flu vaccine development program. This is a critical first test of our HA vaccine candidate, which has the potential to be a highly effective, less expensive and more efficiently produced alternative to current flu vaccines, whose shortcomings have handicapped our ability to address seasonal and potential pandemic flu.”